Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma, Inc. (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
$15.07
<$0.01(<0.01%)
At close: 4:00 PM EST
$15.07
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)1.20M
Market Cap
$330.19M
Enterprise Value-$54.11M
Total Cash (Recent Filing)$170.46M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta4.95
Next Earnings
Mar 19, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-121.63
Shares Outstanding21,910,630
10 Day Avg. Volume1,014,813
30 Day Avg. Volume1,200,329
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap-0.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit32.02
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$38.67Price Target Upside156.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Valuation UpsideAnalyst commentary points to a valuation disconnect versus the probability-adjusted value of telitacicept, indicating potential upside if late-stage data from China are recognized and global studies advance.
Capital And Development FundingThe company has secured funding to initiate a global Phase 3 study in Sjögren's disease, enabling progression of the program without an immediate funding gap.
Clinical ValidationTelitacicept is supported by existing approval and late-stage clinical data in China, which reduces program risk for its global development in autoimmune indications.
Bears Say
Concentration And Timeline RiskReliance on a single asset and a long timeline before first global data create concentration risk that limits near-term upside and keeps some investors cautious.
Financing And Dilution RiskA prior offering priced at a steep discount and resulting share dilution have pressured the stock, and further capital needs could remain an overhang on investor sentiment.
Regulatory And Efficacy Replication RiskApprovals in major markets hinge on a successful Phase 3 readout, and the robust placebo-adjusted results seen in China may be difficult to reproduce in a broader global population.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $330.19M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 50 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on Nov 13, 2025. The company reported -$121.63 earnings per share for the quarter, missing the consensus estimate of -$3.452 by -$118.178.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate is -1.02.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 21,910,630 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$121.63 in its last earnings report, missing expectations of -$3.452. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (156.60% Upside)
$38.67 (156.60% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 27.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.94%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$38.67
▲(156.60% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---